A Phase I Single Center Study of Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

Inclusion Criteria:

- Patients with newly diagnosed choroidal melanoma undergoing proton therapy

- Tumors >15 mm in largest diameter and/or >5 mm in height (recruitment complete)

- Tumors ≤ 15 mm in largest diameter and ≤ 5 mm in height located ≤ 3 mm from optic
disc and/or macula

- Best-corrected visual acuity 20/100 or better in study eye

Exclusion Criteria:

- History of prior treatment for choroidal melanoma

- Pregnancy or lactation

- Presence of diabetic retinopathy

- History of retinal vascular occlusion or other retinal vascular disease

- Active ocular inflammation or history of uveitis in either eye

- History of uncontrolled glaucoma (defined as intraocular pressure >30mmHg despite
treatment with anti-glaucoma medication) or filtering surgery in the study eye

- Previous intravitreal injections of Avastin® in the study eye or in the non-study eye
within 30 days.

- Concurrent use of systemic anti-VEGF therapy